Trial · NCT02249312
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of neutrophils in induced sputum differential cell count | Baseline, Day 1 and 14 | |
| Secondary | Concentration of myeloperoxidase (MPO) in induced sputum | Baseline, Day 1 and 14 | |
| Secondary | Concentration of Interleukin-8 (IL-8) in induced sputum | Baseline, Day 1 and 14 | |
| Secondary | Concentration of tumor necrosis factor (TNF) alpha in induced sputum | Baseline, Day 1 and 14 | |
| Secondary | Differential cell count in induced sputum | Baseline, Day 1 and 14 | eosinophils, basophils, macrophages, lymphocytes and epithelia cells |
| Secondary | Changes in expression of Epidermal growth Factor (EGF) receptors in induced sputum | Day 1 and 14 | only in US center |
| Secondary | Changes in expression of tissue growth factor (TGF) alpha in induced sputum | Day 1 and 14 | only in US center |
| Secondary | Changes in expression of MUC5AC (maximum use concentration) in induced sputum | Day 1 and 14 | only in US center |
| Secondary | Changes in forced expiratory volume in one second (FEV1) | Up to Day 27 after drug administration | assessed by spirometry |
| Secondary | Changes in forced vital capacity (FVC) | Up to Day 27 after drug administration | assessed by spirometry |
| Secondary | Changes in forced expiratory flow (FEF) 25-70% | Up to Day 27 after drug administration | assessed by spirometry |
| Secondary | Changes in FEF50% | Up to Day 27 after drug administration | assessed by spirometry |
| Secondary | Changes in FEF 75% | Up to Day 27 after drug administration | assessed by spirometry |
| Secondary | Changes in peak expiratory flow rate (PEFR) a.m. versus p.m.by patients daily records | Up to Day 27 after drug administration | |
| Secondary | Physician's global evaluation of symptoms assessed on a 6 point severity scale | Baseline, Day 14 | |
| Secondary | Inhibition of MAC-1 expression | Day 1 and 14 | |
| Secondary | Number of patients with Adverse Events | Up to day 27 after drug administration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02249312/registered